皮肤冠状动脉干预技术和技术的进步:临床审查
Yuichi Saito1, Yoshio Kobayashi1
1Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Japan.
Internal medicine (Tokyo, Japan)
|September 29, 2024
概括
穿皮冠状动脉干预 (PCI) 显著改善了心痛和急性冠状动脉综合征患者的治疗结果. 本综述涵盖了近期的技术进步和冠状动脉疾病PCI的未来研究方向.
科学领域:
- 心血管医学 心血管医学
- 干预心脏病学 干预心脏病学
- 医疗技术 医疗技术 医学技术
背景情况:
- 穿皮冠状动脉干预 (PCI) 是对心痛和急性冠状动脉综合征的基石治疗.
- 在过去的40年里,PCI已经取得了重大技术和技术进步.
- 这些改进导致冠状动脉疾病患者的临床结果更好.
研究的目的:
- 审查皮肤穿冠状动脉干预 (PCI) 的最新进展.
- 突出PCI领域有前途的新兴技术.
- 确定干预心脏病学未来研究的重点领域.
主要方法:
- 关于PCI的最新研究和技术发展的文献综述.
- 分析与当代PCI技术相关的临床结果.
- 综合有关新型器械和干预心脏病学的新方法的信息.
主要成果:
- 由于PCI技术和技术已经大大发展,提高了患者的护理.
- 与过去几十年相比,当前时代的PCI显示出明显改善的临床结果.
- 新兴技术显示出进一步优化PCI程序和结果的潜力.
结论:
- 穿皮冠状动脉干预 (PCI) 仍然是一个重要的程序,正在进行创新.
- 持续的研究和技术开发对于推进PCI至关重要.
- 未来的PCI方向旨在进一步改善冠状动脉疾病的管理.
相关概念视频
Coronary Artery Disease V: Surgical Management
3
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
3
Peripheral Artery Disease III: Interprofessional Care
3
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
3
Acute Coronary Syndrome II: Pathophysiology and clinical manifestations
3
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
3
Acute Coronary Syndrome IV: Interprofessional Care
3
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
3
Angina IV: Management
3
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
3
Acute Coronary SyndromeI: Introduction
15
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
15


